Physician profile
Jinyu Lu
NPI 1679834428
$1,253.99
in general payments reported to CMS, 2019-2025
17 companies · $664 in 2025
The $664 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.54 · 2023: $325 · 2024: $250 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978 · Education: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $977.52 |
| Education | $261.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $520.00 | 2023-2025 | Tecvayli, Rybrevant, Carvykti |
| Astrazeneca Pharmaceuticals Lp | $168.94 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $97.55 | 2023 | |
| Celgene Corporation | $86.74 | 2025 | Reblozyl |
| Astellas Pharma US INC | $78.72 | 2024-2025 | Vyloy |
| Seagen INC. | $63.58 | 2023 | Adcetris, Tukysa |
| Merck Sharp & Dohme LLC | $34.77 | 2023-2024 | Keytruda |
| Novartis Pharmaceuticals Corporation | $31.33 | 2025 | |
| Beone Medicines USA, INC. | $26.36 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $24.08 | 2025 | Vanflyta |
| Adc Therapeutics America, INC. | $19.79 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.66 | 2023 | Lifevest |
| Kite Pharma, INC. | $19.37 | 2025 | Yescarta |
| Genzyme Corporation | $17.48 | 2025 | |
| Recordati_rare_diseases_inc. | $16.53 | 2024 | Sylvant |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $14.55 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinyu Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.